Emergence Therapeutics is a European biopharmaceutical company...
Continue Reading-
Emergence Therapeutics raises €87 million Series A financing to advance Nectin-4 ADC
Series A round led by Pontifax and includes new and existing investors Lead product is…
Continue Reading -
Cardior Raises €64 M Series B to Advance Clinical Pipeline of RNA Therapeutics to Treat Cardiac Disease
Oversubscribed round enables late-stage clinical development of lead candidate, a micro-RNA-132 inhibitor, in heart failure…
Continue Reading -
Attgeno appoints Björn Westberg as CFO
Attgeno appoints Björn Westberg as CFO Jul 08, 2021 05:00 UTC Attgeno AB announces today…
Continue Reading -
SAGA Diagnostics raises €10.5 million
SAGA Diagnostics raises SEK 106 million (€10.5 million)...
Continue Reading -
Oncoinvent Secures NOK 250 M in an oversubscribed Pre-IPO Funding Round
Norwegian radiopharmaceutical company announces successful closing of a private placement that will allow the company…
Continue Reading -
Gesynta Pharma announces significant progress across development program for first-in-class drug candidate GS-248
Stockholm, Sweden, June 14 2021 Gesynta Pharma announces significant progress across development program for first-in-class…
Continue Reading -
Abliva reports positive clinical Phase 1a/b results for KL1333 including signs of efficacy in PMD patients
Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biopharmaceutical company developing medicines for the treatment of…
Continue Reading -
Join Hadean Ventures!
April 30, 2021 Hadean Ventures is a fast-growing life science fund manager that invests in…
Continue Reading -
Safety Monitoring Committee Approves 7 MBq as Recommended Clinical Dose for Radspherin®
Safety Monitoring Committee Approves 7 MBq as Recommended Clinical Dose for Radspherin® in the Ongoing…
Continue Reading